Leveraging and Harnessing Generative Artificial Intelligence to Mitigate the Burden of Neurodevelopmental Disorders (NDDs) in Children.
AI could speed NDD care, but only if we pair it with anti-ableist guardrails and solid staff training.
01Research in Context
What this study did
Oleribe (2025) wrote a position paper. He asked how generative AI could help kids with autism, ADHD, and other NDDs.
He did not run an experiment. He reviewed tech reports and policy papers. Then he sketched a plan for using AI in clinics and schools.
What they found
The paper claims AI tools could cut diagnosis wait time by a large share. It also says AI-made lessons could raise attention scores by a large share.
These numbers come from early tech demos, not peer-reviewed trials. The author argues the gains are big enough to act now.
How this fits with other research
McComas et al. (2025) also want fast change, but they warn ableism hides in new tech. They say ask clients what dignity looks like before you buy the software.
Lerman (2024) gives a blueprint for sharing behavior-tech with teachers and nurses. Oleribe skips this step; he assumes AI vendors will train staff for us.
Tullis et al. (2019) push low-tech preference checks in transition plans. Their work reminds us that even smart AI needs to know what the client actually wants.
Why it matters
You may soon be asked to trial an AI screening app. Use Oleribe’s numbers to open the conversation, then pair the tool with McComas’s anti-ableist checklist and Lerman’s training steps. Insist on pilot data before full rollout.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Ask your supervisor for the AI demo script and run it past the client’s stated preferences before you sign off.
02At a glance
03Original abstract
Neurodevelopmental disorders (NDDs) significantly impact children’s health and development. They pose a substantial burden to families and the healthcare system. Challenges in early identification, accurate and timely diagnosis, and effective treatment persist due to overlapping symptoms, lack of appropriate diagnostic biomarkers, significant stigma and discrimination, and systemic barriers. Generative Artificial Intelligence (GenAI) offers promising solutions to these challenges by enhancing screening, diagnosis, personalized treatment, and research. Although GenAI is already in use in some aspects of NDD management, effective and strategic leveraging of evolving AI tools and resources will enhance early identification and screening, reduce diagnostic processing by up to 90%, and improve clinical decision support. Proper use of GenAI will ensure individualized therapy regimens with demonstrated 36% improvement in at least one objective attention measure compared to baseline and 81–84% accuracy relative to clinician-generated plans, customize learning materials, and deliver better treatment monitoring. GenAI will also accelerate NDD-specific research and innovation with significant time savings, as well as provide tailored family support systems. Finally, it will significantly reduce the mortality and morbidity associated with NDDs. This article explores the potential of GenAI in transforming NDD management and calls for policy initiatives to integrate GenAI into NDD management systems.
Healthcare, 2025 · doi:10.3390/healthcare13151898